Prognostic value of chromogranin-a (CGA) compared to circulating tumor cells (CTCs) in metastatic castration resistant prostate cancer (mCRPC).

被引：0
|
作者：
Giridhar, Karthik
Sanhueza, Cristobal T.
Hillman, David W.
Alkhateeb, Hassan
Carlson, Rachel
Tan, Winston
Quevedo, Fernando
Pagliaro, Lance C.
Costello, Brian Addis
Kohli, Manish
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
249
引用
收藏
页数：1
相关论文
共 50 条
  • [11] CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC)
    Ferraldeschi, Roberta
    McDaniel, Andrew
    Krupa, Rachel
    Louw, Jessica
    Tucker, Eric
    Bales, Natalee
    Marrinucci, Dena
    Riisnaes, Ruth
    Mateo, Joaquin
    Dittamore, Ryan
    De Bono, Johann Sebastian
    Tomlins, Scott A.
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [12] Predictive biomarkers in circulating tumor cells to direct management metastatic castration-resistant prostate cancer (mCRPC)
    Scher, Howard I.
    Schonhoft, Joseph
    Dittamore, Ryan
    CANCER RESEARCH, 2019, 79 (13)
  • [13] Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
    Lozano, Rebeca
    Lorente, David
    Aragon, Isabel M.
    Romero-Laorden, Nuria
    Nombela, Paz
    Mateo, Joaquim
    Reid, Alison H. M.
    Cendon, Ylenia
    Bianchini, Diletta
    Llacer, Casilda
    Sandhu, Shahneen K.
    Sharp, Adam
    Rescigno, Pasquale
    Garces, Teresa
    Pacheco, Maria I.
    Flohr, Penelope
    Massard, Christophe
    Lopez-Casas, Pedro P.
    Castro, Elena
    de Bono, Johann S.
    Olmos, David
    CANCERS, 2021, 13 (10)
  • [14] Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program.
    Massard, Christophe
    Oulhen, Marianne
    Le Moulec, Sylvestre
    Loriot, Yohann
    Auger, Nathalie
    Beuzeboc, Philippe
    Albiges, Laurence
    Culine, Stephane
    Oudard, Stephane
    Hennequin, Christophe
    Vielh, Philippe
    Farace, Francoise
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [15] Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
    Rini, Brian I.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (03) : 163 - 164
  • [16] Circulating tumor cells in metastatic castration-resistant prostate cancer
    Brian I. Rini
    Current Oncology Reports, 2009, 11 : 163 - 164
  • [17] Prognostic significance of circulating tumor cells in castration resistant prostate cancer
    Zima, T.
    Mikulova, V.
    Jancikova, M.
    Capoun, O.
    Soukup, V.
    Honova, H.
    Sirova, M.
    FEBS JOURNAL, 2013, 280 : 390 - 390
  • [18] Prognostic Value of Circulating Tumor Cells in Castration Resistant Prostate Cancer: A Meta-analysis
    Zheng, Yuxiao
    Zhang, Cheng
    Wu, Jie
    Cheng, Gong
    Yang, Haiwei
    Hua, Lixin
    Wang, Zengjun
    UROLOGY JOURNAL, 2016, 13 (06) : 2881 - 2888
  • [19] Assessment of serial serum chromogranin A (CGA) and CGA/PSA ratio and treatment response with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Lewis, Akeem Ronell
    Costello, Brian Addis
    Quevedo, Fernando
    Pagliaro, Lance C.
    Weinshilboum, Richard M.
    Wang, Leiwei
    Kalari, Krishna Rani
    Kohli, Manish
    Tan, Winston
    Giridhar, Karthik
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17036 - E17036
  • [20] Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Khalaf, Daniel
    Annala, Matti
    Beja, Kevin
    Vandekerkhove, Gillian
    Zulfiqar, Muhammad
    Finch, Daygen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345